share_log

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

SEC ·  Nov 14 05:17
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more